Neuraxis (NRXS) Cash from Financing Activities (2022 - 2025)
Neuraxis (NRXS) posted Cash from Financing Activities of $2.6 million for Q4 2025, up 1529.74% sequentially from -$183808.0 in Q3 2025, and down 49.4% YoY from $5.2 million in Q4 2024.
Neuraxis (NRXS) Cash from Financing Activities (2022 - 2025) Analysis & Trends
Neuraxis has reported Cash from Financing Activities for 4 years, with the latest figure at $2.6 million in Q4 2025.
- Quarterly Cash from Financing Activities fell 49.4% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (down 19.62% YoY) and the FY2025 annual result came in at $7.8 million, down 19.62% from the prior year.
- Cash from Financing Activities rose to $2.6 million in Q4 2025 per NRXS's latest filing, from -$183808.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $5.5 million in Q2 2025 and troughed at -$183808.0 in Q3 2025.
- A 4-year average of $1.8 million and a median of $1.1 million in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 419.48% in 2024, then sank 105.17% in 2025.
- Over 4 years, Cash from Financing Activities stood at $510009.0 in 2022, then soared by 284.88% to $2.0 million in 2023, then jumped by 164.61% to $5.2 million in 2024, then tumbled by 49.4% to $2.6 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.6 million, -$183808.0, and $5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.63 Mn |
| Dec 31, 2025 | 2.63 Mn |
| Sep 30, 2025 | -183,808.00 |
| Sep 30, 2025 | -183,808.00 |
| Jun 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 5.46 Mn |
| Mar 31, 2025 | -69,845.00 |
| Mar 31, 2025 | -69,845.00 |
| Dec 31, 2024 | 5.19 Mn |
| Dec 31, 2024 | 5.19 Mn |
| Sep 30, 2024 | -107,219.00 |
| Sep 30, 2024 | -107,219.00 |
| Jun 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Sep 30, 2023 | 3.57 Mn |
| Sep 30, 2023 | 3.57 Mn |